Efficacy of Liposomal Bupivacaine for Pain Control After Percutaneous Nephrostolithotomy
Status:
Withdrawn
Trial end date:
2017-08-08
Target enrollment:
Participant gender:
Summary
Percutaneous nephrostolithotomy (PCNL) is a common endoscopic procedure performed for upper
urinary tract calculus disease. Despite being minimally invasive, it is associated with
significant postoperative pain, often necessitating inpatient hospitalization and narcotic
pain medications. Additionally, one of a number of catheters is often left protruding from
the access tract for a period of time following the procedure, adding to patient discomfort.
Attempts have been made to study peri-tubular or access tract analgesic installation, which
have shown promise.1-2 However, no studies, to our knowledge, have examined the use of
liposomal bupivacaine preparations in this regard. In this study we hope to prospectively
analyze the use of liposomal bupivacaine injected to the access tract site at the time of
PCNL and determine its effects on postoperative narcotic requirement and pain scores.
Patients presenting for PCNL will be randomized to either the liposomal bupivacaine or usual
care, which involves no injection of local anesthesia. Patients will then be followed during
their inpatient stay. Total narcotic requirement (in milligrams) and pain scores (using
Wong-Baker FACES rating scale) will be compared.3 Typical postoperative care and discharge
criteria will not change during the course of this study.